{"entity":{"id":"nct04851717","kind":"trial","name":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures","aka":[],"tldr":"A phase 2/3 trial of Remimazolam in childhood cancers, run by Acacia Pharma Ltd, active and no longer recruiting.","summary":"Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures is a phase 2/3 interventional study registered as NCT04851717 by Acacia Pharma Ltd, with 100 participants enrolled, started 2021-11-15 and due to reach its primary completion in 2027-10. Interventions recorded: Remimazolam.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04851717","url":"https://clinicaltrials.gov/study/NCT04851717"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["acacia-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04851717","phase":"2/3","setting":"A Phase 2/3, Prospective, Open-label Trial Evaluating the Efficacy, Safety, and Pharmacokinetics of Remimazolam for Intravenous Sedation in Paediatric Patients Undergoing Diagnostic and/or Therapeutic Procedures","sponsor":"Acacia Pharma Ltd","enrolled":100,"outcomes":[]},"route":"/trials/nct04851717/","neighbours":{"cancer":[{"id":"childhood-cancers","kind":"cancer","name":"Childhood cancers (all types)","route":"/cancers/childhood-cancers/"}],"company":[{"id":"acacia-pharma","kind":"company","name":"Acacia Pharma","route":"/companies/acacia-pharma/"}]}}